Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Anticancer properties of Prunus mume extracts (Chinese plum, Japanese apricot).

Bailly C.

J Ethnopharmacol. 2019 Sep 3;246:112215. doi: 10.1016/j.jep.2019.112215. [Epub ahead of print] Review.

PMID:
31491438
2.

Lack of effect of the combination of metyrapone and oxazepam on brain dopamine.

Keller CM, Goeders NE.

Brain Res. 2019 Sep 3;1724:146435. doi: 10.1016/j.brainres.2019.146435. [Epub ahead of print]

PMID:
31491421
3.

Gingival Ischemia and Petechiae in a Patient Medicated With PCSK9 Inhibitor for Hypercholesterolemia: An Adverse Drug Event?

Thermos G, Tosios KI.

Clin Adv Periodontics. 2019 Mar;9(1):20-23. doi: 10.1002/cap.10043. Epub 2018 Sep 28.

PMID:
31490035
4.

Averting Alert Fatigue to Prevent Adverse Drug Reactions.

Carroll AE.

JAMA. 2019 Aug 20;322(7):601. doi: 10.1001/jama.2019.11710. No abstract available.

PMID:
31429887
5.

Practical risk management in early phase clinical trials.

Coates S, Täubel J, Lorch U.

Eur J Clin Pharmacol. 2019 Apr;75(4):483-496. doi: 10.1007/s00228-018-02607-8. Epub 2018 Dec 19.

PMID:
30569285
6.

A Biomimetic Gold Nanocages-Based Nanoplatform for Efficient Tumor Ablation and Reduced Inflammation.

Xu Q, Wan J, Bie N, Song X, Yang X, Yong T, Zhao Y, Yang X, Gan L.

Theranostics. 2018 Oct 24;8(19):5362-5378. doi: 10.7150/thno.27631. eCollection 2018.

7.

Awakening p53 in vivo by D-peptides-functionalized ultra-small nanoparticles: Overcoming biological barriers to D-peptide drug delivery.

Bian Z, Yan J, Wang S, Li Y, Guo Y, Ma B, Guo H, Lei Z, Yin C, Zhou Y, Liu M, Tao K, Hou P, He W.

Theranostics. 2018 Oct 22;8(19):5320-5335. doi: 10.7150/thno.27165. eCollection 2018.

8.

Explaining all without causing unnecessary harm: Is there scope for positively framing medical risk information?

Webster RK, Weinman J, Rubin GJ.

Patient Educ Couns. 2019 Mar;102(3):602-603. doi: 10.1016/j.pec.2018.09.014. Epub 2018 Sep 15.

PMID:
30243771
9.

[Does a physician have to inform the patient about the rare risk of priapism before administering an anticoagulant?]

Vogeler M.

Unfallchirurg. 2018 Aug;121(8):674-676. doi: 10.1007/s00113-018-0521-8. Review. German.

PMID:
29947832
10.

More Than the Trajectory of the Teeth, We Need to Know About the Treatment Trajectory of Patients.

Baltzan M, Rizzo D.

J Clin Sleep Med. 2018 Jan 15;14(1):7-8. doi: 10.5664/jcsm.6866. No abstract available.

11.

Review of cancer treatment with immune checkpoint inhibitors : Current concepts, expectations, limitations and pitfalls.

Thallinger C, Füreder T, Preusser M, Heller G, Müllauer L, Höller C, Prosch H, Frank N, Swierzewski R, Berger W, Jäger U, Zielinski C.

Wien Klin Wochenschr. 2018 Feb;130(3-4):85-91. doi: 10.1007/s00508-017-1285-9. Epub 2017 Nov 2. Review.

12.

Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma.

Shoushtari AN, Friedman CF, Navid-Azarbaijani P, Postow MA, Callahan MK, Momtaz P, Panageas KS, Wolchok JD, Chapman PB.

JAMA Oncol. 2018 Jan 1;4(1):98-101. doi: 10.1001/jamaoncol.2017.2391.

Supplemental Content

Loading ...
Support Center